<DOC>
	<DOCNO>NCT00042055</DOCNO>
	<brief_summary>Patients moderately severely active Crohn 's disease treat oral CP-461 200 mg ( 2 x 100 mg capsule ) twice-daily 8 week . The purpose study see CP-461 improves symptoms Crohn 's disease and/or patient 's quality life . Patient 's safety monitor throughout study .</brief_summary>
	<brief_title>CP-461 Treatment Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Men woman &gt; = 18 year age . Crohn 's Disease Activity Index ( CDAI ) &gt; = 220 &lt; = 400 . Crohn 's disease least 3 month duration colitis , ileitis , ileocolitis , confirm radiography endoscopy . Men woman childbearing potential must use adequate birth control measure ( e.g . abstinence , oral contraceptive , intrauterine device , barrier method spermicide , surgical sterilization ) . Concomitant medication : If use aminosalicylates , patient must use aminosalicylates least 2 month prescreening . The dose must stable least 2 week prescreening . If aminosalicylates discontinue , must do least 2 week prescreening . If use oral corticosteroid , patient must receive least 2 month must stable dosage ( &lt; = 40 mg/day prednisone equivalent ) least 2 week prescreening . If use infliximab , patient must receive infliximab infusion least 12 week . If use azathioprine , 6mercaptopurine ( 6MP ) , mycophenolate mofetil , start date must least 3 month prior prescreening dose must stable least 8 week prescreening . If use methotrexate , patient must use methotrexate least 4 month prescreening stable dosage least 6 week . If use Crohn 's diseasespecific antibiotic , patient must use least 2 week stable dosage . The screening laboratory test must meet following criterion : Hemoglobin &gt; = 8.5 WBC &gt; = 3.5 x 10 9/L Neutrophils &gt; = 1.5 x 10 9/L Platelets &gt; = 100 x 10 9/L Serum creatinine le 2.2 mg/dL . Transaminases ( AST/ALT ) must &lt; = 1.5 time upper limit normal range laboratory conduct test . Bilirubin must WNL . Patient must able adhere study visit schedule protocol requirement . The patient must capable give informed consent consent must obtain study specific screen procedure . Local manifestation Crohn 's disease stricture , abscess , disease complication surgery might indicate . Conditions might preclude utilization CDAI ass response therapy ( `` short gut '' syndrome ) . If abscess present , drain prescreening , least 3 week drainage abscess prescreening . Positive stool culture enteric pathogen , pathogenic ovum parasites Clostridium difficile toxin . Pregnancy , nursing , unwillingness comply birth control . Patients currently receive treat cyclosporine , tacrolimus , sirolimus within 4 week prescreening . Infliximab infusion within 12 week prescreening . Rectally administered steroid within 2 week prescreening . Treatment parenteral nutrition ( TPN ) within 3 week prescreening . Signs symptom severe , progressive , uncontrolled renal , hepatic , hematologic , endocrine , pulmonary , cardiac , neurologic , cerebral disease . Presence transplant organ . Malignancy within past 5 year ( except squamous basal cell carcinoma skin treat evidence recurrence ) . Known substance abuse ( drug alcohol ) last two year . Patients fever &gt; = 100.5 degree F. The patient unable return followup evaluation . The patient receive investigational drug device within 30 day initiation therapy . Refusal sign inform consent . The patient , opinion investigator , appropriate candidate study . The following laboratory abnormality : Hemoglobin &lt; 8.5 WBC &lt; 3.5 x 10 9/L Neutrophils &lt; 1.5 x 10 9/L Platelets &lt; 100 x 10 9/L Serum creatinine &gt; = 2.2 mg/dL Transaminases ( AST/ALT ) &gt; 1.5 time upper limit normal range laboratory conduct test . Bilirubin &gt; upper limit normal range laboratory conduct test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Inflammatory Bowel Disease</keyword>
</DOC>